Week of Jan. 2, 2012: AMRI Restructures; ISPE Appoints Nancy S. Berg as CEO; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Jan. 2, 2012: AMRI Restructures; ISPE Appoints Nancy S. Berg as CEO; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company Notes

Karo Bio, a pharmaceutical company, has entered into a research collaboration agreement with Pfizer to discover and develop small-molecule RORgamma modulators for the treatment of autoimmune diseases. Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive right to market any products that may be developed as a result of the collaboration. Karo Bio may receive up to $217 million in upfront and milestone payments in addition to potential royalty fees.
Read More

Marina Biotech, an oligonucleotide-based drug discovery and development company, and the biotechnology company Mirna Therapeutics have formed a license agreement regarding the development and commercialization of microRNA-based therapeutics using Mirna’s proprietary microRNAs and Marina Biotech's liposomal delivery technology.
Read More

The biopharmaceutical company OPKO Health has completed its acquisition of FineTech Pharmaceutical, an Israeli provider of APIs.
Read More

The biopharmaceutical company Zealand Pharma has received a milestone payment of EUR 3 million ($3.9 million) received under the license agreement with Helsinn Healthcare for elsiglutide, a GLP-2 peptide agonist in Phase I development.
Read More

Abbott and Emergent Biosolutions have ended their partnership on a cancer drug candidate.

The CMO Albany Molecular Research (AMRI) restructures.

Alexion has agreed to acquire Enobia in a deal valued over $1 billion.

Arecor has formed a collaboration with Lilly to develop advanced formulations of protein therapeutics.

UCB and Immunomedics have restructured their epratuzumab license agreement.

Veloxis and Athena have formed a manufacturing and commercialization pact for AtorFen, a fixed-dose combination of fenofibrate and atorvastin.

People Notes

Shlomo Yanai, president and CEO of Teva, plans to retire from the company effective May 2012. Teva’s board of directors has named Jeremy Levin, a former senior executive at Bristol-Myers Squibb, to succeed Yanai at that time. Rob Koremans will succeed Gerard van Odijk as president and CEO of Teva Europe.
Read More

Celgene has announced the appointment of Richard Bagger as senior vice-president of corporate affairs and strategic market access.

ISPE has announced Nancy S. Berg as its new CEO.

Marken has appointed Steve Roese as its new head of global quality assurance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here